GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (STU:17Q1) » Definitions » Price-to-Owner-Earnings

Pharmaron Beijing Co (STU:17Q1) Price-to-Owner-Earnings : 179.00 (As of Dec. 11, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharmaron Beijing Co Price-to-Owner-Earnings?

As of today (2024-12-11), Pharmaron Beijing Co's share price is €1.79. Pharmaron Beijing Co's Owner Earnings per Share (TTM) ended in Sep. 2024 was €0.01. It's Price-to-Owner-Earnings for today is 179.00.


The historical rank and industry rank for Pharmaron Beijing Co's Price-to-Owner-Earnings or its related term are showing as below:

STU:17Q1' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 112.43   Med: 242.36   Max: 5470
Current: 332.58

During the past 10 years, the highest Price-to-Owner-Earnings of Pharmaron Beijing Co was 5470.00. The lowest was 112.43. And the median was 242.36.


STU:17Q1's Price-to-Owner-Earnings is ranked worse than
93.21% of 162 companies
in the Biotechnology industry
Industry Median: 31.44 vs STU:17Q1: 332.58

As of today (2024-12-11), Pharmaron Beijing Co's share price is €1.79. Pharmaron Beijing Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €0.14. Therefore, Pharmaron Beijing Co's PE Ratio (TTM) for today is 13.16.

As of today (2024-12-11), Pharmaron Beijing Co's share price is €1.79. Pharmaron Beijing Co's EPS without NRI for the trailing twelve months (TTM) ended in was €0.14. Therefore, Pharmaron Beijing Co's PE Ratio without NRI for today is 12.52.

During the past 10 years, Pharmaron Beijing Co's highest PE Ratio without NRI was 145.96. The lowest was 16.57. And the median was 63.38.


Pharmaron Beijing Co Price-to-Owner-Earnings Historical Data

The historical data trend for Pharmaron Beijing Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co Price-to-Owner-Earnings Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 144.44 426.67 -

Pharmaron Beijing Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 99.50 -

Competitive Comparison of Pharmaron Beijing Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pharmaron Beijing Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Price-to-Owner-Earnings falls into.



Pharmaron Beijing Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pharmaron Beijing Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.79/0.01
=179.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaron Beijing Co  (STU:17Q1) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pharmaron Beijing Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. The company's operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.

Pharmaron Beijing Co Headlines

No Headlines